TNF Pharmaceuticals, Inc. (LON: 0A8D)

Market Cap	2.55M
Revenue (ttm)	n/a
Net Income (ttm)	-21.57M
Shares Out	n/a
EPS (ttm)	-9.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10
Average Volume	1,013
Open	1.159
Previous Close	n/a
Day's Range	1.159 - 1.159
52-Week Range	0.888 - 6.233
Beta	n/a
RSI	44.26
Earnings Date	Apr 3, 2025

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company’s second drug platform, Supera-CB...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 6
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A8D

Financial Performance

Financial numbers in USD